SAN FRANCISCO, March 05, 2025 (GLOBE NEWSWIRE) — A class action lawsuit has been filed against Maravai LifeSciences (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators. The suit, captioned Nelson v. Maravai Lifesciences Holdings, et al., No. 3:25-cv-00499-AGS-AHG (S.D. Cal.), represents investors who purchased Maravai securities between August 7, 2024 and February 24, 2025.
Hagens Berman is investigating the alleged claims and urges Maravai investors who suffered substantial losses to submit your losses now.
Class Period: Aug. 7, 2024 – Feb. 24, 2025
Lead Plaintiff Deadline: May 5, 2025
Visit: www.hbsslaw.com/investor-fraud/mrvi
Contact the Firm Now: MRVI@hbsslaw.com
844-916-0895
Maravai LifeSciences Holdings, Inc. (MRVI) Securities Class Action:
The litigation is focused on the propriety of Maravai’s assurances that its financial statements are prepared in accordance with applicable accounting rules and that its internal controls over financial reporting are sufficient.
The complaint alleges that Maravai made false and misleading statements while failing to disclose crucial information. Specifically, the suit contends that …
